Clinical Trials Evaluating GVAX in Prostate Cancer Now Enrolling Patients

Cancer Connect

Two clinical trials evaluating the immunotherapy agent GVAX for the treatment of hormone-refractory prostate cancer are currently enrolling patients.

The prostate is a gland of the male reproductive system. It produces some of the fluid that transports sperm during ejaculation. After skin cancer, prostate cancer is the most common form of cancer diagnosed in men.

Current treatment options for prostate cancer include watchful waiting, surgery, chemotherapy, radiation, or hormonal therapy. Hormonal therapy is designed to block testosterone from stimulating the growth of hormone-dependent types of prostate cancer.

Some prostate cancers become resistant to hormonal therapy and then require a different treatment approach; this condition is known as hormone refractory prostate cancer (HRPC).

Because hormone refractory prostate cancer can be difficult to treat, new methods-such as immunotherapy agents-are being explored. The goal of these approaches is to produce an immune response that helps the body fight cancer cells.

GVAX is an immunotherapy agent that stimulates the patient’s immune system to target and kill cancerous prostate cells. GVAX has demonstrated sustained anticancer activity in the treatment of HRPC and is currently in the last phases of clinical trials prior to FDA review for the treatment of HRPC.

Patients with HRPC may wish to speak with their physician regarding their individual risks and benefits of participating in these clinical trial further evaluating GVAX. For more information and to learn where these trials are available, please visit:




For an expanded listing of clinical trials, go to:

Related News:

GVAX® Treatment Combination Highly Effective in Hormone-Refractory Prostate Cancer (6/4/2006)

GVAX® Immunotherapy Promising for Hormone-Refractory Prostate Cancer (2/28/2006)

Copyright Prostate Cancer Information Center on

Copyright © 2018 CancerConnect. All Rights Reserved.


Prostate Cancer